Shuttle Pharmaceuticals is expected to report second-quarter 2026 revenue of $0.00 and a consensus EPS of $0.00, with the stock trading at $4.07 against an analyst price target of $0.94.
Investors are focused on the company’s radical strategic pivot into Dogecoin mining after acquiring United Dogecoin Inc. and abandoning its core oncology pipeline. This report is expected to provide updates on the deployment of its ElphaPex DG1+ mining fleet and the status of renewable energy contracts in Idaho.
The shift follows significant cash burn and the termination of lead clinical trials in late 2025, marking a total transformation into a digital asset infrastructure play.